Last year we wrote about the Bailey, Perrin & Bailey law firm, which made significant campaign contributions to the 2006 reelection campaign of Pennsylvania Governor Ed Rendell. The firm was later awarded a no-bid contingency fee contract to sue Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, over marketing of its drug Risperdal.
Fortunately, this sort of eyebrow-raising partnership is not common in New Jersey, where the Corzine Administration operated in accordance with the Private Attorney Retention Sunshine Act (PARSA), throughout his administration. NJLRA applauded the Executive Order issued by the Governor in late 2009.
A judge dismissed the Commonwealth’s suit against Janssen, citing a lack of evidence. While this is a step in the right direction for New Jersey-based Johnson & Johnson, there are other legal challenges ahead. Businessweek reports that the same law firm will be representing the state of South Carolina against Janssen Pharmaceuticals., Litigation against its once-popular drug could cost the company billions of dollars. The firm was a large financial contributor to state officials in South Carolina as well.